Form 4: Kura Oncology Director Sells Shares Under 10b5-1 Plan

Kura Oncology Director Faheem Hasnain reported the acquisition and subsequent sale of 10,000 common shares under a pre-arranged Rule 10b5-1 plan.

Summary

• Faheem Hasnain, a Director of Kura Oncology, Inc., reported transactions involving the company's common stock on December 9, 2025.
• The transactions included the acquisition of 10,000 shares of common stock at an exercise price of $3.12 per share.
• Concurrently, 10,000 shares of common stock were disposed of at a weighted average sale price of $10.9764 per share, with individual trades ranging from $10.60 to $11.53.
• Both the acquisition and disposition were executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Hasnain on September 8, 2025.
• Following these transactions, Mr. Hasnain's direct beneficial ownership of Kura Oncology common stock stands at 23,983 shares.

Sentiment

Score: 5

Explanation: The transactions represent a pre-planned sale by a director under a Rule 10b5-1 plan, which is a routine insider transaction and does not necessarily reflect a change in sentiment regarding the company's future.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled event rather than a reaction to new, non-public information.
• The sale price of $10.9764 is significantly higher than the exercise price of $3.12, indicating a profitable transaction for the director.

Negatives

• A director's sale of shares, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, although this is mitigated by the 10b5-1 plan.

Future Outlook

This Form 4 filing, detailing an insider transaction, does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are routine disclosures in the public markets. This specific filing does not provide information to suggest broader industry trends or competitive shifts.

Stakeholder Impact

• Shareholders: The impact on shareholders is likely minimal as this is a routine, pre-planned insider transaction. It does not signal new fundamental information about the company.

Key Dates

Recommendation

The filing details a pre-planned insider transaction (exercise and sale) under a Rule 10b5-1 plan. Such routine transactions by a director do not typically provide new fundamental information to alter an investment recommendation. Investors should continue to hold based on the company's underlying business fundamentals rather than this specific insider trade.

Keywords

Kura Oncology, KURA, Faheem Hasnain, Form 4, insider trading, stock sale, 10b5-1 plan, director, common stock